Search

632 Result(s)
Sort by

CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
vaxxitek® hvt + ibd + nd

vaxxitek® hvt + ibd + nd

Bursal Disease-Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector; the vaccine includes a diluent
Patient Organizations

Patient Organizations

Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.